Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30

The Company presentation will take place today at 4:15 p.m. ET, and can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at https://app.webinar.net/bwLr50QqD7v. The webcast will also be available for replay following the event. The slide deck used in the presentation can be found on https://ir.co-dx.com/.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.  

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-302570821.html

SOURCE Co-Diagnostics